Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 23, 2024 -- During August 2021 to August 2023, the prevalence of adult hypertension was 47.7 percent, with hypertension higher in men than women, according to an October data brief published by the National Center for Health Statistics.
Cheryl D. Fryar, M.S.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the National Health and Nutrition Examination Survey to examine the prevalence, awareness, treatment, and control of hypertension among U.S. adults during August 2021 to August 2023.
The researchers found that the prevalence of adult hypertension was 47.7 percent during August 2021 to August 2023. Hypertension was higher in men than women (50.8 versus 44.6 percent) and increased with age: 23.4, 52.5, and 71.6 percent for ages 18 to 39, 40 to 59, and 60 years and older, respectively. Overall, 59.2 percent of those with hypertension were aware of their hypertension status. Of adults with hypertension, 51.2 percent were currently taking medication to lower blood pressure. One-fifth (20.7 percent) of adults with hypertension had their blood pressure controlled to less than 130/80 mm Hg. From 2017-March 2020 to August 2021-August 2023, there was no significant change seen in awareness, treatment, or control of hypertension.
"Based on recent national data from August 2021 through August 2023, the prevalence of hypertension remains above the Healthy People 2030 target goal to lower blood pressure to 41.9 percent of the population or below," the authors write. "However, the prevalence of controlled hypertension at 20.7 percent is higher than the Healthy People 2030 target goal of 18.9 percent or above."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-24 12:00
Read more
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
- AI Helps Spot Brain Tumor Tissue Surgeons Miss
- Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma
- Use of Fan, Skin Wetting Reduces Cardiac Strain in Hot, Humid Conditions
- USPSTF Recommends Early Screening for Syphilis in Pregnancy
- AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions